NASDAQ : BMEA

Biomea Fusion, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 0.6228 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 45.14M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Details

NameBiomea Fusion, Inc.
SectorHealthcare
IndustryBiotechnology
Employees37
Founded2017
Ipo Date2021-04-16
CeoMichael J. Hitchcock
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price17.00
IsinUS09077A1060
Cusip09077A106
Cik1840439
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Dr. Michael J. M. Hitchcock Ph.D.Interim Chief Executive Officer and Director
Ramses M. ErdtmannCo-Founder, President, Chief Operating Officer and Director
Heow TanChief Technical and Quality Officer
Caroline Perez- Dupont J.D.Senior Vice President of Legal
Dr. Thorsten Kirschberg Ph.D.Executive Vice President of Research
Dr. Stephan Morris M.D.Chief Development Officer
Ravi Upasani Ph.D.Executive Vice President of Intellectual Property

Contact

Address1599 Industrial Road, San Carlos, California 94070, United States
Phone650 980 9099
Websitehttps://biomeafusion.com